Skip to content
1 WOMEN'S HEALTHWOMEN'S & REPRODUCTIVE HEALTH

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.

Records
5,000
Last changed
Update schedule
55 1 * * * UTC
Coverage
05/26/2000–10/09/2026
Method
Methodology
Title
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Record Date
10/01/2026
Vuga Group
INTERVENTIONAL
Change Status
not-comparable
Recency Days
9.75
Research Attention Score
90.246